Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qualigen Therapeutics ( (QLGN) ) just unveiled an announcement.
On September 29, 2025, Qualigen Therapeutics announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. This financing marks a pivotal moment for the company as it embarks on a strategic transformation into a crypto-focused business, with plans to establish a new venture called CXC10. The investment will support the development of a crypto business centered on three growth engines, including the C10 Digital Asset Treasury, an AI-powered crypto trading agent, and ecosystem tokens. This move positions Qualigen to bridge traditional sectors with AI and crypto, aiming to become a leading U.S. public company in this space.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Qualigen Therapeutics, Inc. is a company operating in the biotechnology sector, primarily focusing on therapeutic products. The company is undergoing a strategic transformation to incorporate Web3 and cryptocurrency elements into its business model, with plans to rebrand as CXC10.
Average Trading Volume: 2,357,989
Technical Sentiment Signal: Hold
Current Market Cap: $9.48M
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.